The Motley Fool·2025-03-05 12:00Group 1: Verizon Communications - Verizon's stock has increased by approximately 6% over the last 12 months, driven by investor optimism regarding potential declines in interest rates [3] - The company is projected to achieve single-digit percentage top-line growth in 2024, with wireless service revenue expected to rise between 2% and 2.8% for the full year [4] - Verizon's free cash flow is anticipated to be between $17.5 billion and $18.5 billion, significantly exceeding the $11.2 billion paid out in dividends over the past year [4] - The stock is currently trading at a forward price-to-earnings (P/E) multiple of just 9, making it an attractive option for buy-and-hold investors [5] Group 2: Toronto-Dominion Bank - Toronto-Dominion Bank offers a dividend yield of 4.9%, which is considered high for a leading financial institution [6] - The stock has faced negative sentiment following a $3 billion fine related to money laundering failures and indefinite caps on its U.S. retail banking operations [6] - Despite current challenges, there is optimism that the bank can recover by implementing effective anti-money-laundering controls [7] - The stock trades at a forward P/E of just 11, indicating it may be a promising investment opportunity [8] Group 3: Pfizer - Pfizer currently provides a dividend yield of 6.5%, which is exceptionally high for a blue-chip healthcare stock [9] - The stock has been undervalued due to market uncertainties surrounding the healthcare industry and the company's reliance on vaccines [9] - Pfizer's revenue increased by 12% operationally last year, excluding the impact of its COVID-19 vaccine and antiviral pill [10] - The company has a robust portfolio with over 300 approved drugs and a pipeline of 115 drug candidates, including a promising weight loss drug candidate, danuglipron [11] - Given its current valuation, Pfizer may deserve a higher price, and investing in it could yield substantial returns over time [11]